A regulatory review that took much longer than usual and ended in a restricted indication that leaves little scope for the product in question to carve out a meaningful place in the relevant treatment pathway. Reviewers suggesting that a different comparator might have achieved better results and that using the comparator in question may have distorted the results in favor of the product under review. Clinical trials involving 572 individuals recruited in 275 sites across 33 countries.
All this and more is contained in the 174-page European
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?